About 30% breast cancer patients in poor treatment

Breast cancer treatment to be divided into yin and yang principle, can not be generalized, HER2-positive breast cancer is difficult, the prognosis is not so optimistic. Breast cancer has become in Beijing, Shanghai, Guangzhou, Shenzhen and other cities in developed regions of China represented the most common cancer in women, which accounted for Jin Sancheng HER2-positive breast cancer. It and the general breast cancer compared to the more dangerous and poor prognosis.

HER2-positive breast cancer was Jinsan Cheng

Many people may not know, there are yin and yang of breast cancer law can not be unified treat! The past, we should always generally, early detection of breast cancer, early treatment, in fact, breast cancer is a group (family) disease, the human epidermal growth factor from receptor -2 (HER2) overexpression is divided into HER2 positive and HER2-negative breast cancer.

HER2-positive means "human epidermal growth factor receptor 2 overexpression." Means: "She" has been activated, the signal is passed to stimulate the proliferation of cancer cells crazy, so HER2-positive patients often precedes endocrine therapy is not sensitive to rapid tumor progression, prone to lymph node or hematogenous metastasis, poor prognosis. In breast cancer patients, who showed Jinsan Cheng HER2 positive breast cancer are "diehards", not only rapid tumor progression, treatment is also very difficult.

Did not do half of HER2 testing in breast cancer patients

Although the popularization of knowledge with the disease, public awareness of prevention and treatment of breast cancer also increased, but the national survey data, only 57% of breast cancer patients have HER2 testing. Distinguish yin and yang, it is easy to miss treatment opportunities. Subtypes to determine which specific treatment with, otherwise the treatment of excessive or unreasonable treatment, will give an adverse impact on survival of breast cancer patients. JISHOU said.

According to reports, HER2 detection methods There are three, namely, immunohistochemistry (IHC), show in situ hybridization (CISH) and fluorescence in situ hybridization (FISH). Typically, patients with IHC do first check, if the test results is 3 plus, he was diagnosed with HER2-positive; if the result is a plus or a 0, compared with HER2-negative; If the test results is 2 plus doctor will do it again CISH or FISH were checked for the final diagnosis. If CISH or FISH tests positive, he was diagnosed with HER2-positive, or negative.

Targeted therapy can reduce the risk of HER2-positive breast cancer death

Breast cancer is the control effect of the medical profession generally considered one of the better tumor. However, for the treatment of HER2 positive breast cancer more difficult, according to the traditional surgery, chemotherapy and endocrine therapy, there are still many patients with distant recurrence. This part of the patients, the need for early selection of targeted therapy. National Comprehensive Cancer Network (NCCN) guidelines recommend the Chinese version of CNCCN HER2-positive patients with trastuzumab with adjuvant chemotherapy program. This means that, while patients in the chemotherapy for targeted therapy. Currently, the global research and clinical application showed that this treatment can be targeted to HER2-positive early breast cancer recurrence rate has dropped 52%, 35% reduction in the risk of death; advanced HER2-positive breast cancer up to 61% remission rate .

Posted in Breast cancer patients